ClinicalTrials.gov
public full text
Public Domain
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer. PURPOSE: This phase II trial is studying how well zoledronic acid works in preventing musculoskeletal symptoms in post-menopausal women with stage I, stage II, or stage III breast cancer receiving letrozole.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions#865515
- Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)#1086968
- Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma#902433
- The Use of Zoledronic Acid to Complex Regional Pain Syndrome#888105
- A Pilot Trial of IV Pamidronate for Low Back Pain#1102340
Record · ID 1096184
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive